Welcome to my new Substack, where I will be sharing analyses, thoughts, papers, and anything that I feel could be interesting, mostly related to oncology and medicine in general.
, which I was co-editing with , is currently not active, as Vinay is now on a mission for us as the Chief Medical and Scientific Officer (CMO and CSO) and as the Director of the Center for Biologics Evaluation and Research (CBER) at the US FDA!This first post is a recent video we recorded with researchers from the VKPrasadLab and others. During this meeting, we talked about a recent paper published in the European Journal of Cancer, co-authored with Giuseppe Salfi, entitled:
“When suboptimal post-protocol care in oncology trials is rewarded”.
I wanted this video to be a tribute to Vinay. Vinay, we miss you, my friend!
During the meeting, we covered the topic of post-protocol care in oncology, including crossover, with definitions, examples of suboptimal post-protocol care, and how it can distort overall survival results in oncology trials. We also drew possible solutions. All you want to know about post-protocol care and how it can distort overall survival results in oncology trials!
I hope you will enjoy it.
Welcome to The Oncology Shot with Timothee Olivier.
